Femasys (NASDAQ:FEMY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Femasys (NASDAQ:FEMY) from a strong sell rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Maxim Group decreased their target price on Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Lake Street Capital cut their target price on Femasys to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Femasys Stock Down 1.2%

FEMY stock opened at $1.63 on Friday. Femasys has a 12 month low of $1.46 and a 12 month high of $22.20. The firm has a market cap of $13.66 million, a PE ratio of -0.46 and a beta of -2.16. The firm has a 50 day simple moving average of $2.46 and a 200 day simple moving average of $4.63. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.14 and a quick ratio of 0.55.

Femasys (NASDAQ:FEMY) last issued its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Insider Transactions at Femasys

In other Femasys news, CFO Dov Elefant bought 15,625 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at approximately $50,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of Femasys stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 38,750 shares of company stock valued at $124,000 over the last 90 days. Corporate insiders own 7.75% of the company’s stock.

About Femasys

Femasys Inc is a biomedical company focused on developing and commercializing therapies and technologies for women’s health. The company’s products are designed to address reproductive health needs, including contraception and infertility, through minimally invasive procedures intended to be performed in a physician’s office.

Femasys’ product portfolio includes FemaSeed, an FDA-cleared intratubal insemination system designed to deliver sperm directly into the fallopian tube during an infertility treatment procedure.